BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 19616945)

  • 1. Benzothiophene inhibitors of MK2. Part 1: structure-activity relationships, assessments of selectivity and cellular potency.
    Anderson DR; Meyers MJ; Kurumbail RG; Caspers N; Poda GI; Long SA; Pierce BS; Mahoney MW; Mourey RJ
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4878-81. PubMed ID: 19616945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benzothiophene inhibitors of MK2. Part 2: improvements in kinase selectivity and cell potency.
    Anderson DR; Meyers MJ; Kurumbail RG; Caspers N; Poda GI; Long SA; Pierce BS; Mahoney MW; Mourey RJ; Parikh MD
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4882-4. PubMed ID: 19616942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.
    Richardson CM; Williamson DS; Parratt MJ; Borgognoni J; Cansfield AD; Dokurno P; Francis GL; Howes R; Moore JD; Murray JB; Robertson A; Surgenor AE; Torrance CJ
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1353-7. PubMed ID: 16325401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).
    Lovering F; Kirincich S; Wang W; Combs K; Resnick L; Sabalski JE; Butera J; Liu J; Parris K; Telliez JB
    Bioorg Med Chem; 2009 May; 17(9):3342-51. PubMed ID: 19364658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and optimization of p38 inhibitors via computer-assisted drug design.
    Goldberg DR; Hao MH; Qian KC; Swinamer AD; Gao DA; Xiong Z; Sarko C; Berry A; Lord J; Magolda RL; Fadra T; Kroe RR; Kukulka A; Madwed JB; Martin L; Pargellis C; Skow D; Song JJ; Tan Z; Torcellini CA; Zimmitti CS; Yee NK; Moss N
    J Med Chem; 2007 Aug; 50(17):4016-26. PubMed ID: 17658737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping.
    Richardson CM; Nunns CL; Williamson DS; Parratt MJ; Dokurno P; Howes R; Borgognoni J; Drysdale MJ; Finch H; Hubbard RE; Jackson PS; Kierstan P; Lentzen G; Moore JD; Murray JB; Simmonite H; Surgenor AE; Torrance CJ
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3880-5. PubMed ID: 17570665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design.
    Kontopidis G; Andrews MJ; McInnes C; Plater A; Innes L; Renachowski S; Cowan A; Fischer PM
    ChemMedChem; 2009 Jul; 4(7):1120-8. PubMed ID: 19472269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrazolobenzodiazepines: part I. Synthesis and SAR of a potent class of kinase inhibitors.
    Liu JJ; Daniewski I; Ding Q; Higgins B; Ju G; Kolinsky K; Konzelmann F; Lukacs C; Pizzolato G; Rossman P; Swain A; Thakkar K; Wei CC; Miklowski D; Yang H; Yin X; Wovkulich PM
    Bioorg Med Chem Lett; 2010 Oct; 20(20):5984-7. PubMed ID: 20832307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics.
    Zeng Q; Bourbeau MP; Wohlhieter GE; Yao G; Monenschein H; Rider JT; Lee MR; Zhang S; Lofgren J; Freeman D; Li C; Tominey E; Huang X; Hoffman D; Yamane H; Tasker AS; Dominguez C; Viswanadhan VN; Hungate R; Zhang X
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1652-6. PubMed ID: 20137932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of cyclin D1-CDK4: synthesis, biological evaluation and structure-activity relationships. Part 2.
    Horiuchi T; Nagata M; Kitagawa M; Akahane K; Uoto K
    Bioorg Med Chem; 2009 Dec; 17(23):7850-60. PubMed ID: 19889545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Alkenylthieno[2,3-b]pyridine-5-carbonitriles: Potent and selective inhibitors of PKCtheta.
    Nathan Tumey L; Boschelli DH; Lee J; Chaudhary D
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4420-3. PubMed ID: 18606543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors.
    Wrobleski ST; Lin S; Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Gillooly KM; Shuster DJ; McIntyre KW; Doweyko AM; Kish KF; Tredup JA; Duke GJ; Sack JS; McKinnon M; Dodd J; Barrish JC; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2739-44. PubMed ID: 18364256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination.
    Griffin RJ; Henderson A; Curtin NJ; Echalier A; Endicott JA; Hardcastle IR; Newell DR; Noble ME; Wang LZ; Golding BT
    J Am Chem Soc; 2006 May; 128(18):6012-3. PubMed ID: 16669651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A practical synthesis of the major 3-hydroxy-2-pyrrolidinone metabolite of a potent CDK2/cyclin A inhibitor.
    Nesi M; Borghi D; Brasca MG; Fiorentini F; Pevarello P
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3205-8. PubMed ID: 16616492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-amino-pyrazoles as potent and selective p38α inhibitors.
    Das J; Moquin RV; Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Newitt JA; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6886-9. PubMed ID: 21035336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of triazolopyridazinones as potent p38α inhibitors.
    Herberich B; Jackson C; Wurz RP; Pettus LH; Sherman L; Liu Q; Henkle B; Saris CJ; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1226-9. PubMed ID: 22196117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors.
    Lin S; Wrobleski ST; Hynes J; Pitt S; Zhang R; Fan Y; Doweyko AM; Kish KF; Sack JS; Malley MF; Kiefer SE; Newitt JA; McKinnon M; Trzaskos J; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5864-8. PubMed ID: 20732813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
    Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK.
    Hom RK; Bowers S; Sealy JM; Truong AP; Probst GD; Neitzel ML; Neitz RJ; Fang L; Brogley L; Wu J; Konradi AW; Sham HL; Tóth G; Pan H; Yao N; Artis DR; Quinn K; Sauer JM; Powell K; Ren Z; Bard F; Yednock TA; Griswold-Prenner I
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7303-7. PubMed ID: 21071223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.